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Clustered regularly interspaced short palindromic repeats (CRISPR) screening is a powerful toolset for investigating diverse biological processes. Most CRISPR screens to date have been performed with in vitro cultures or cellular transplant models. To interrogate cancer in animal models that more closely recapitulate the human disease, autochthonous direct in vivo CRISPR screens have recently been developed that can identify causative drivers in the native tissue microenvironment. By empowering multiplexed mutagenesis in fully immunocompetent animals, direct in vivo CRISPR screens enable the rapid generation of patient-specific avatars that can guide precision medicine. This Opinion article discusses the current status of in vivo CRISPR screens in cancer and offers perspectives on future applications.
CRISPR-Mediated Genome Editing Meets the Complexity of the Cancer Genome
Over the past decade, tremendous efforts have been devoted to profiling patient cancers. Multi-institutional consortia such as The Cancer Genome Atlas have now profiled over 10 000 tumors, generating petabytes of high-dimensional data that illuminate the complexities of several cancer types [1] . Although the molecular portraits of cancer are now in higher resolution than ever before, the path to clinical translation for many cancer types remains largely unexplored.
The central issue is that cancer genomics can inform what mutations are present, but has limited power to indicate which ones are functionally important [2, 3] . Individual tumors often have hundreds, if not thousands, of molecular aberrations. While some of these alterations are found in well-established oncogenes (see Glossary) and tumor suppressors, many novel aberrations occur in previously uncharacterized or even unannotated regions, making it difficult to reliably discern whether they are actually driving the progression of a given cancer. Furthermore, different patients can present with unique combinations of these various mutations that can drastically influence a cancer's growth pattern, tendency to metastasize, and susceptibility to therapy.
CRISPR-mediated genome editing has become a powerful tool in cancer biology due to its programmability and flexibility [4] . In addition to its canonical use for targeted gene knockouts [5, 6] , CRISPR has been reengineered for a variety of purposes including transcriptional activation [7, 8] , transcriptional repression [9] , histone modification [10] , base editing [11, 12] , DNA methylation [13] [14] [15] , and genome architecture manipulation [16] . Following in the footsteps of RNAi screens, the modularity of CRISPR has naturally lent itself to high-throughput screening approaches [17] . By designing custom libraries of single-guide RNAs (sgRNAs), one can simultaneously screen large collections of genomic elements (coding genes, regulatory elements such as enhancers, noncoding RNAs, or other noncoding features) in a given biological context [18] . Here we review the development and application of in vivo CRISPR screens.
In Vivo CRISPR Screens to Interrogate the Complexities of Cancer
CRISPR screens were first developed by using pooled sgRNA libraries to target all annotated genes in the human genome [19, 20] . High-throughput, and particularly genome-wide, CRISPR screens combine the power of forward genetics and reverse genetics. Such approaches offer an unbiased yet precisely targeted method of identifying genes that contribute to a phenotype, such as cancer progression. Compared with random mutagenesis, CRISPR screens use customized sgRNA libraries, while simultaneously preserving the 'randomness' during selection. Unlike RNAi screens, CRISPR generates precise mutations or complete knockouts instead of partial gene knockdown or silencing, which has been shown to facilitate higher between-construct concordance and lower off-target rates [21, 22] . CRISPR screens have thus become the state-of-the-art approach for the discovery of genetic drivers and phenotypic modulators in many biological contexts.
In cancer, CRISPR screens have been performed to identify genes involved in a wide variety of processes [23] , including regulators of drug resistance [24] [25] [26] [27] [28] , synergistic and synthetic lethal interactions [29, 30] , regulators of PD-L1 expression [31] , and essential genes [32] [33] [34] ( Figure 1 ). While in vitro studies are valuable for identifying cell-intrinsic properties of cancer cells and potential therapeutic windows ( Figure 2A , Key Figure) , they cannot address problems involving complex interactions between multiple cell types that reflect the bona fide nature of cancer as an organ, instead of a collection of isolated tumor cells [35] . As highlighted by recent advances in cancer immunotherapy, the microenvironmental milieu is constantly engaged in conversation with tumor cells, with significant clinical consequences [36] [37] [38] [39] [40] . To more faithfully Glossary a Cas9: an endonuclease that is directed to specific sites in the genome by CRISPR spacers, where it induces double-stranded breaks in the target DNA. Clustered regularly interspaced short palindromic repeats (CRISPR): segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of 'spacer DNA' from previous exposures to a bacteriophage virus or plasmid. The CRISPR-Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present in plasmids and phages. Cas proteins use the CRISPR spacers to recognize and cut these exogenous genetic elements in a manner analogous to RNAi in eukaryotic organisms. By delivering the Cas9 nuclease and appropriate guide RNAs (gRNAs) into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added. CRISPR-associated endonuclease in Prevotella and Francisella 1 (Cpf1): also known as Cas12a; a CRISPR-guided endonuclease that can be utilized for targeted genome editing in diverse species. Unlike Cas9, Cpf1 does not require a tracrRNA for DNA cleavage, and has the capability to autonomously process crRNA arrays. CRISPR RNA (crRNA): the short RNA sequence that directly guides CRISPR nucleases to target sites in the genome that is independent of the scaffold sequence present in fulllength sgRNAs. Single-guide RNA (sgRNA): a term generally interchangeable with gRNA in genome editing with the CRISPRCas9 system. Synthetic lethality: arises when a combination of mutations in two or more genes leads to cell death, whereas a mutation in only one of these genes does not. In a synthetic lethal genetic screen, it is necessary to begin with a mutation that does not kill the cell, although it may confer a phenotype (e.g., slow growth) and then systematically test other mutations at additional loci to determine which ones confer lethality. Synthetic lethality indicates functional relationships between genes.
recapitulate the human disease for enhanced translational accuracy, it is essential to investigate these phenomena in vivo where cancers can develop in the context of a tissue microenvironment.
To date, virtually all in vivo CRISPR screens have aimed to investigate phenotypes of cancer, directly demonstrating the power and simplicity of this technology in oncology. The first in vivo CRISPR screen investigated annotated genes in the mammalian genome and their potential to promote tumor growth and metastasis when mutagenized [41] . In this study, the authors introduced a genome-wide sgRNA library into a non-metastatic cancer cell line. The poolmutagenized cell library was then subcutaneously transplanted into the back skin of nude mice and monitored for metastasis to the lung. By sequencing the sgRNAs present in the metastases, the authors identified and subsequently validated a panel of hits from the initial screen that functionally drove lung metastasis. Multiple in vivo CRISPR screens have since been performed to identify tumor suppressors [42] [43] [44] , oncogenes [45] , synthetically lethal genes [46] , and regulators of cancer immunotherapy, in both two-cell type (2-CT) coculture systems [47] and transplant tumor models [48] , among others. A common thread in these studies is their twostep workflow: the sgRNA library is first introduced to cells in culture, followed by transplantation into mice to assess phenotypes in vivo. After a selection phase (e.g., expression of a reporter, outgrowth of a tumor, resistance to therapy), the cells are sequenced to identify enriched and/or depleted sgRNAs ( Figure 2B ).
Limitations of Transplant-Based In Vivo CRISPR Screens
By virtue of them having a microenvironment, compared with in vitro CRISPR screens, it is anticipated that in vivo studies more faithfully model carcinogenesis as it occurs in humans. However, transplant-based in vivo screens have significant limitations. First, introducing large numbers of cancer cells into mice clearly does not resemble the normal process of tumorigenesis. Second, transplantations are commonly performed subcutaneously, rather than orthotopically in the relevant organs. In addition, immunodeficient mice are often used to promote the grafting efficiency of the mutagenized cell library, limiting the applicability of these models for investigation of cancer-immune interactions. Moreover, the engraftment efficiency of transferred cells can vary from cell line to cell line and from host to host. Furthermore, there exist multiple cellular bottlenecks of tumor evolution in vivo, such as the circulation limit during the metastasis cascade. Finally, the native organ microenvironment places numerous constraints on transplanted cells even in orthotopic settings. These limitations can affect the preclinical utility of cancer-cell transplant-based in vivo CRISPR screens.
Direct In Vivo CRISPR Screens to More Faithfully Recapitulate Human Cancers
To better model the natural context of cancer as it occurs in humans, the following features can provide guiding principles for more accurate in vivo CRISPR screens in cancer: (i) the tumors being modeled derive from the endogenous target tissue; (ii) the immune system remains intact; and (iii) the corresponding tissue microenvironment is preserved. These challenges can be overcome by directly mutagenizing target tissues in vivo rather than using a transplant approach.
A number of studies have demonstrated efficient CRISPR-mediated in vivo mutagenesis directly at the target organ site. In the liver, hydrodynamic injection of sgRNA-containing plasmids into the tail veins of Cas9 mice was sufficient to induce multiplexed mutagenesis in hepatocytes [49] , while in the lung intratracheal delivery of sgRNA-carrying lentiviruses was able to induce mutagenesis directly in Cas9-expressing lung epithelial cells [50] . Through the use of adenoassociated viruses (AAVs), direct mutagenesis in the mouse brain was also shown to be feasible [51] . Because Cas9 and other genome-editing RNA-guided nucleases (RGNs) are large proteins, generation of Cas9 transgenic animals [52] [53] [54] simplifies the delivery of CRISPR components and facilitates direct in vivo mutagenesis.
Extending on these direct in vivo CRISPR techniques, autochthonous CRISPR screens of varying scales have now been performed in a few organ systems ( Figure 2C ). Hydrodynamic injection of plasmids with sgRNA and Cas9 expression cassettes flanked by Sleeping Beauty (SB) inverted repeats, along with a SB-transposase vector, has been utilized to screen ten sgRNAs for their ability to induce CRISPR-mediated tumorigenesis in a Kras
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-sensitized mouse liver [55] . As another approach, lentiviral pools were utilized to screen 11 sgRNAs for their ability to drive lung tumorigenesis in Cre-driven Cas9 mice [56] . Finally, stereotaxic delivery of an AAV sgRNA library directly into the mouse brain efficiently induced glioblastomas that recapitulate the pathologic features of the human disease [57] , which enabled direct and quantitative assessment of the tumorigenicity of 280 sgRNAs targeting 56 genes. Of note, the relative mutant frequencies of these genes in the AAV-based model significantly correlated with the mutant frequencies observed in human glioblastoma cohorts. Delivery of AAV-CRISPR sgRNA pools intravenously followed by captured sequencing using customized probesets [57] or molecular inversion probe sequencing [58] allows autochthonous mapping of causative functional variants directly in the targeted genomic loci, as demonstrated in the brain [57] and liver [58] . Facilitated by the high efficiency of AAV-mediated transduction, various significantly co-occurring pairs were identified, thereby pinpointing synergistic driver pairs in tumorigenesis.
Nevertheless, direct in vivo approaches have their share of limitations. Optimal technical parameters that are easily achievable in in vitro or cell line transplant settings (i.e., 'indirect' in vivo), such as library size, coverage, and multiplicity of infection (MOI), are much more challenging with a direct in vivo approach. Therefore, the size of a sgRNA library must be controlled to ensure adequate coverage in vivo. With an oversized library, random sampling errors from low viral transduction rates will invariably lead to many spurious positive and negative 'hits'. Other key constraints include the number of tumor-originating cells in the native organ, the accessibility of such cells due to the complexity of cellular organization in endogenous tissues, uncharacterized or unknown cell-cell interactions, the viral transduction efficiency, and immune rejection. To this end, it is worth noting that AAV-mediated approaches have the major advantage of higher-titer, higher direct in vivo transduction efficiencies and provoke minimal immune reactions [57] , thus enabling larger CRISPR libraries to be screened more efficiently in an autochthonous setting. Since AAVs usually do not integrate into the genome, the relative abundance of sgRNAs in tumors cannot be ascertained by sgRNA cassette sequencing as is commonly done for lentivirus-based screens. Instead, the AAVmediated approach requires capture sequencing of the sgRNA target regions to functionally extract the mutational signatures of the tumors.
Direct In Vivo CRISPR Pooled Mutagenesis Technologies for Precision Medicine
With further improvements and modifications, we envision that direct in vivo CRISPR screens could be widely applied in multiple facets of precision medicine. Using the genomic information from a patient's tumor, a personalized CRISPR library could be readily designed to directly generate disease mimics, or cancers encompassing the same set of mutations, to investigate the behaviors of those mutations in mice ( Figure 3A) . As a proof of principle, high-titer AAV libraries have been successfully used to infect single cells at high MOI in vivo, leading to genetically complex tumors with several mutations [57, 58] . This 'mouse avatar' approach Tumor immunity: refers to the interaction between the host immune system and a tumor. In different contexts, the immune system can have opposing roles towards cancer progression. Cancer immunotherapies aim to tip the scales towards immune-mediated elimination of the tumor. Tumor microenvironment: the stroma and supporting milieu surrounding the tumor, usually comprising fibroblasts, immune cells, and endothelial cells. Tumor suppressor gene: also known as an antioncogene; a gene that protects a cell from one step on the path to cancer. Mutations that inactivate tumor suppressors will contribute to cancer progression. commonly used, as they can stably integrate into the host genome. After a selection phase to enrich for a desired phenotype, the sgRNA cassettes are amplified from genomic DNA and sequenced to identify the top candidate genes. (B) Indirect in vivo screens follow the same steps as in vitro studies, but the selection phase occurs in a recipient animal. Following transplantation of the mutagenized cell pool into mice, different mutants will become enriched. In the case of a tumorigenesis screen, highly abundant sgRNAs in the resultant tumors would be brought forward as candidate tumor suppressors. (C) For direct in vivo screens, CRISPR mutagenesis occurs at the would enable robust enumeration of the tumorigenic potential of each mutation present in a patient's tumor. More importantly, rapid generation of such disease mimics allows robust therapeutic testing of approved or novel treatments in genetically matched tumors. This type of approach could then be utilized to predict the outcomes of treatments in patients and potentially anticipate which specific tumors would exhibit sensitivity or resistance to chemo-, targeted, or immune therapies, and thus be leveraged for prioritization of therapies.
It was recently demonstrated that patient-derived tumor xenografts (PDXs) adopt evolutionary courses divergent from the human primary tumor [59] . While this effect is likely to be due in large part to intrinsic differences between mice and humans, a key contributing factor may lie in the method, as xenografts generally require immunodeficient hosts for successful engraftment. The development and application of humanized mice [60] has helped to bridge this gap in part, particularly with regard to innate immunity, although complete humanization of the full immune system remains to be seen. By contrast, direct in vivo models are designed to originate from the autochthonous tissue site in fully immunocompetent mice. For these reasons, we anticipate that direct in vivo CRISPR screens will more faithfully recapitulate the behavior and evolutionary course of human cancers.
Intratumoral heterogeneity is increasingly being recognized as an important feature of human cancers, potentially contributing to drug resistance and relapse [61, 62] . In addition to cell-type heterogeneity and microenvironmental variations, intratumoral heterogeneity is often characterized by distinct subclonal mutation signatures that differentially influence cellular behavior [63] . To this end, AAV-mediated direct in vivo CRISPR screens are particularly well equipped to model the heterogeneity present in human cancers. As demonstrated in the brain and liver, AAV-CRISPR approaches can rapidly create genetically complex multiclonal tumors in individual mice [57, 58] . This immense heterogeneity inherent to AAV-mediated CRISPR screens could be exploited to investigate clonal dynamics in tumors, serving as a discovery platform for how tumor subclones interact in controlled experimental settings in otherwise wild-type organisms.
Concluding Remarks
Recent development and applications of in vivo CRISPR screens have showcased their power for unbiased identification of functional genetic elements. Particularly, direct in vivo CRISPR screens offer a high-throughput strategy to interrogate candidate genes for their ability to drive tumorigenesis from the autochthonous tissue. Unlike in vitro or transplant-based approaches, direct in vivo CRISPR studies retain the endogenous tissue microenvironment and can be performed in fully immunocompetent animals at high efficiency. Future studies will need to explicitly evaluate whether direct in vivo CRISPR models better recapitulate human disease (see Outstanding Questions). A key experiment would be to compare the in vivo evolutionary trajectory of a primary patient tumor and the corresponding mouse avatar, with or without therapeutic selection pressure.
The design philosophy behind most CRISPR screens is to study the effects of single-gene mutations on a desired phenotype. However, many biological processes are driven by interactions between multiple genes. In cancer, the precise combinations of mutations in individual autochthonous target organ site instead of in culture. Lentiviral and adenoassociated virus (AAV) approaches have both been successfully used for multiplexed direct in vivo mutagenesis. Intravenous, intracranial, and intratracheal viral injections can drive tumorigenesis from the liver, brain, and lung, respectively. Since AAVs do not integrate into the genome, capture sequencing must be performed to read out the results of the screen (i.e., highly abundant indel variants).
Outstanding Questions
Does a corresponding CRISPR-engineered mouse avatar mimic the drug response of a genetically matched tumor from a patient?
Can in vivo CRISPR screens be effectively leveraged for the study of complex genetic interactions in cancer?
How can direct in vivo CRISPR screens be efficiently coupled with other high-throughput approaches such as single-cell sequencing and high-content imaging to enable the dissection of highly heterogeneous cancers?
Can direct in vivo CRISPR screens be utilized to deduce mutations that are associated with sensitivity to immunotherapy as well as those conferring primary or acquired resistance?
How can in vivo CRISPR screens be effectively used in immune cells to identify novel regulators of the tumor microenvironment?
Mul -KO viral pool Direct in vivo mul -KO screen tumors can lead to strikingly diverse behaviors, influencing tumor aggressiveness and clinical response. In this regard, in vivo CRISPR screens can be readily applied to identify phenotypic modulators on specific sensitized backgrounds. For instance, direct in vivo CRISPR screens could be used to identify factors that influence the metastatic properties of mutant Kras-driven tumors. An exciting avenue for further work is the adaptation of CRISPR-associated endonuclease in Prevotella and Francisella 1 (Cpf1) [64, 65] to in vivo cancer modeling. Like Cas9, the Cpf1 RGN can be used for precisely targeted genome editing, yet it has unique multiplexing capabilities due to its independence from a tracrRNA [64, 65] . Cpf1 has just begun to emerge for higher-dimensional genetic screening of tumor growth and metastasis in vivo [66] and remains to be more broadly applied for other aspects of cancer. The development of this technology would enable high-dimensional screening of different mutation combinations, potentially leading to the identification of novel synergistic or synthetically lethal genetic interactions in cancer ( Figure 3B ).
Additionally, the application of dCas9-activator mice could enable the functional identification of oncogenes directly in vivo, providing an orthogonal perspective to preexisting tumor suppressor screens [67] . Similarly, mice engineered to express CRISPR-targeted base editors might offer an approach to screen specific point mutations that drive tumorigenesis from the autochthonous tissue. It would also be interesting to apply single-cell RNA-seq (scRNA-seq) to tumors generated by direct in vivo CRISPR screens [68] [69] [70] . Together, these technologies would enable the creation and subsequent dissection of cancer heterogeneity at ultrahigh resolution ( Figure 3C ). To further provide spatial information, multiplexed fluorescent in situ hybridization (MERFISH) [71] could potentially be adapted for the purpose of sequencing sgRNA pools directly in tissue sections. These data would allow matched comparisons between CRISPR-induced mutational signatures and histopathological phenotypes ( Figure 3D ).
Finally, direct in vivo CRISPR screens can be readily applied for studies in cancer immunity, as these models are fully functional in immunocompetent animals. A key question on the forefront of immunooncology is to understand why only a fraction of patients respond to immunotherapy, such as checkpoint inhibitors. Multiplexed AAV-CRISPR screens could be applied in the context of checkpoint blockade to deduce which mutations are associated with sensitivity to immunotherapy, as well as those conferring primary or acquired resistance. With further technological development, direct in vivo screens on primary immune cell populations may also become feasible, allowing high-throughput interrogation of factors that regulate immune responses against tumors.
As these technologies continue to develop and mature, they can be adapted for personalized cancer modeling and tumor driver profiling as well as the identification of novel and relevant therapeutic targets. Emerging new technologies such as direct in vivo CRISPR screens continue to transform oncology discovery. vivo CRISPR screens can be readily used to generate personalized mouse avatars. CRISPR libraries can be customized to the mutations present in a given patient's tumor. Following autochthonous mutagenesis, therapeutic candidates can be evaluated using the mouse avatars, informing clinical decision-making. (B) Higherdimensional screens (i.e., double, triple, n-tuple knockouts) using CRISPR-associated endonuclease in Prevotella and Francisella 1 (CRISPR-Cpf1) offer an elegant, high-throughput approach to investigate genetic interactions. Such studies could uncover synergistic driver mutations and synthetically lethal combinations, which may help to inform patient prognostication and to identify novel therapeutic vulnerabilities. (C) Direct in vivo CRISPR mutagenesis drives the formation of genetically complex, multiclonal tumors. Coupled with single-cell capture sequencing and RNA-seq, direct in vivo CRISPR screens offer a powerful approach for the generation and subsequent dissection of tumor heterogeneity. (D) In vivo CRISPR screens thus far have lacked spatial resolution, as single-guide RNA (sgRNA) sequencing and/or capture sequencing is performed on genomic DNA extracted from dissociated cell suspensions. By combining direct in vivo CRISPR mutagenesis with multiplexed in situ hybridization, it may be feasible to perform clonal analysis and phenotype-genotype matching on tissue sections.
